Why Invest?

The Opportunity

The Compound Growth Rate of Controlled Substance is 5.34% In 2023 it is $88.95 billion and by 2032 it’s expected to be $142.11 billion. Given the importance of safety, the most appropriate route to market is through a clinical, pharmaceutical setting.

Access to prescription opioids became more difficult starting in 2015. Fentanyl entered the street market at this time. Overdose deaths continue to rise, and experts predict a stimulant crisis is next. Almost half of accidental apparent opioid toxicity deaths Jan-Mar 2023 also involved a stimulant. Occasional users are also victims of the toxic drug supply.

The underlying cause of addiction is often unaddressed trauma. Psychedelic-assisted therapy is effective at treating both. In fact, researchers see this as a breakthrough treatment. Mental health disorders are a related and urgent health crisis worldwide. According to a Harvard study, the medical cost of mental health conditions is estimated to rise by $6 trillion by 2030.

Our Approach

Sunshine Labs acknowledges the global impact of the Toxic Drug Crisis. As the decriminalization of controlled substances expands, we are poised to provide and distribute products to our international partners. In Canada, dialogue with local health authorities and all levels of government continues.

We can help save lives by working with experts on the leading edge of this crisis. Making legitimate, safer supply available to these experts allows them to do their work safely. This work is evidence-based with extensive research funded through Health Canada.

The licence also allows the supply controlled substances to further medical research. Our goals include offering medical devices to save lives and provide support during recovery. Addiction treatment and trauma support are an integral part of the Solution.

Get started

Accomplishments

Phase 1

Health Canada Certified Building to Secure Dealer’s License. Completed May 2022.

Strategically planned to be small and scalable shortening the timeline from lab construction to licensing. Aimed to meet, but not exceed the current legal market for controlled substances.
Development of current and European Good Manufacturing Practices (c/euGMP) and associated Standard Operating Procedures (SOPs) for production and sales.
Current target markets include international buyers and local health authorities.
Regulatory amendments approved by Health Canada for psychedelics, controlled substances and Natural Product Numbers (NPNs).

Phase 2

Build Partnerships. Secure Agreements Internationally 2023/24.

Supply agreements with international pharmaceutical manufacturers and distributors for controlled substances, pharmaceutical products and medical devices.
Procurement of international purchase agreements and purchase orders from pharmaceutical wholesalers.
Developing national partnerships with harm reduction organizations. Research of what the market needs by speaking with primary care experts.
Inititiating international partnerships for the provision of psychedelic medicine to addiction and mental health in psychiatry.

Phase 3

Add Site 2. Secure Precursor’s License. Obtain Import Permit 2025.

Strategically planned to be 4,000 square feet and follow c/euGMP to meet demand from the growing controlled substances marketplace.
Concentrating on the active compounds from whole plant extracts as well as synthetically-derived products will allow us to access both the natural and manufactured drug markets. Precursor’s license obtained.
Fulfilling our own demands and then offering white-labeled products to other companies will help to close the supply gap thus increasing profitability.
Building international relationships to import and export ethically sourced medical products. First import permit obtained.